BLOG

endpoints

Sotio partners with Merck to test lead candidate with Keytruda; DC’s KeifeRx raises $6M in Series A — and brings on two new board members

Sotio has been on a roll lately. The quiet Czech biotech based in Prague got a massive $315 million raise last week, and now the biotech announced today that it’s joined in on a collaboration with Merck to evaluate a combo of Sotio’s lead candidate SOT101 with Merck’s PD-1 antibody Keytruda.